After a year that has been anything but smooth sailing, pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is closing out 2025 on a positive note. Shares received a significant 7% boost on Dec. 23. That day, markets reacted to the U.S. Food and Drug Administration's (FDA) approval of Novo’s weight loss pill.
While Novo shares have delivered a total return of around -40% in 2025 as of the Dec. 30 close, the FDA approval is a development that could catalyze stronger performance for NVO stock in 2026. Let’s dive into the difficulties that Novo has faced in 2025 and gain an updated outlook on the stock going forward.
